1. ¹Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
2. ²Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan
3. ³Hepatobiliary and Pancreatic Medical Oncology Division, National Cancer Center Hospital East, Chiba, Japan
4. ⁴Radiation Oncology Division, National Cancer Center Hospital East, Chiba, Japan

Correspondence: Dr M Ikeda, E-mail: masikeda@ncc.go.jp

Received 5 February 2007; Revised 18 April 2007; Accepted 18 April 2007.

Abstract

This study investigated the maximum tolerated dose of S-1 based on the frequency of its dose-limiting toxicities (DLT) with concurrent radiotherapy in patients with locally advanced pancreatic cancer. S-1 was administered orally at escalating doses from 50 to 80 mg m^-2 b.i.d. on the day of irradiation during radiotherapy. Radiation therapy was delivered through four fields as a total dose of 50.4 Gy in 28 fractions over 5.5 weeks, and no prophylactic nodal irradiation was given. Twenty-one patients (50 three; 60 five; 70 six; 80 mg m^-2 seven patients) were enrolled in this trial. At a dose of 70 mg m^-2 S-1, two of six patients demonstrated DLT involving grade 3 nausea and vomiting and grade 3 haemorrhagic gastritis, whereas no patients at doses other than 70 mg m^-2 demonstrated any sign of DLT. Among the 21 enrolled patients, four (19.0%) showed a partial response. The median progression-free survival time and median survival time for the patients overall were 8.9 and 11.0 months, respectively. The recommended dose of S-1 therapy with concurrent radiotherapy is 80 mg m^-2 day^-1. A multi-institutional phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway.